The demise of multidrug-resistant HIV-1: the national time trend in Portugal
Authors:
- Jurgen VercauterenJVJurgen Vercauteren
- E. ValadasEVE. Valadas
- E. TeofiloETE. Teofilo
- D. FariaDFD. Faria
- J. VeraJVJ. Vera
- Anne-Mieke VandammeAVAnne-Mieke Vandamme
Open Access
- 9 December 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 68 (4) , 911-914
Abstract
Despite a decreasing mortality and morbidity in treated HIV-1 patients, highly active antiretroviral treatment (HAART) can still fail due to the development of drug resistance. Especially, multidrug-resistant viruses pose a threat to efficient therapy. We studied the changing prevalence of multidrug resistance (MDR) over time in a cohort of HIV-1-infected patients in Portugal. We used data of 8065 HIV-1-infected patients followed from July 2001 up to April 2012 in 22 hospitals located in Portugal. MDR at a specific date of sampling was defined as no more than one fully active drug (excluding integrase and entry inhibitors) at that time authorized by the Portuguese National Authority of Medicines and Health Products (INFARMED), as interpreted with the Rega algorithm version 8.0.2. A generalized linear mixed model was used to study the time trend of the prevalence of MDR. We observed a statistically significant decrease in the prevalence of MDR over the last decade, from 6.9% (95% CI: 5.7–8.4) in 2001–03, 6.0% (95% CI: 4.9–7.2) in 2003–05, 3.7% (95% CI: 2.8–4.8) in 2005–07 and 1.6% (95% CI: 1.1–2.2) in 2007–09 down to 0.6% (95% CI: 0.3–0.9) in 2009–12 [OR = 0.80 (95% CI: 0.75–0.86); P < 0.001]. In July 2011 the last new case of MDR was seen. The prevalence of multidrug-resistant HIV-1 is decreasing over time in Portugal, reflecting the increasing efficiency of HAART and the availability of new drugs. Therefore, in designing a new drug, safety and practical aspects, e.g. less toxicity and ease of use, may need more attention than focusing mainly on efficacy against resistant strains.Keywords
This publication has 12 references indexed in Scilit:
- Temporal Changes in the Epidemiology of Transmission of Drug-Resistant HIV-1 across the World2012
- Drug resistance in HIV-1Current Opinion in Virology, 2011
- FDA notifications. Complera approved.2011
- Time to get serious about HIV antiretroviral resistanceThe Lancet Infectious Diseases, 2011
- HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational studyThe Lancet Infectious Diseases, 2011
- Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapyJournal of Antimicrobial Chemotherapy, 2011
- Transmission of Drug‐Resistant HIV‐1 Is Stabilizing in EuropeThe Journal of Infectious Diseases, 2009
- The Management of Treatment‐Experienced HIV‐Infected Patients: New Drugs and Drug CombinationsClinical Infectious Diseases, 2009
- The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001–2006) in PortugalRetrovirology, 2008
- Declining Prevalence of HIV-1 Drug Resistance in Treatment-Failing Patients: A Clinical Cohort StudyAntiviral Therapy, 2007